MErCuRIC Abstract Accepted to ASCO 2015

MErCuRIC will be presented at the American Society of Clinical Oncology (ASCO) 2015 meeting, 29 May – 02 June 2015, in Chicago.

A poster entitled ‘MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients’ will be included in the Gastrointestinal (Colorectal) Cancer poster session.